Orionis has developed multiple technology platforms for the discovery of new generations of therapeutics and precision medicines whose pharmacological activities are directed by design to disease targets, avoiding undesired off-target interactions and potentially associated drug liabilities. Our technology platforms further enable access to a broad range of target types to address multiple key disease vulnerabilities for the development of novel therapies.